Page 153 - Haematologica-April 2018

TNF receptor signaling as therapeutic target in CLL
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib. N Engl J Med. 2014;370(24):2286-2294.
13. Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002;100(4):1215-1219.
14. Adami F, Guarini A, Pini M, et al. Serum levels of tumour necrosis factor-alpha in patients with B-cell chronic lymphocytic leukaemia. Eur J Cancer. 1994;30A(9):1259- 1263.
15. Bojarska-Junak A, Hus I, Szczepanek EW, Dmoszynska A, Rolinski J. Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. Leuk Res. 2008;32(2):225-233.
16. Digel W, Porzsolt F, Schmid M, Herrmann F, Lesslauer W, Brockhaus M. High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia. J Clin Invest. 1992;89(5):1690-1693.
17. Digel W, Stefanic M, Schoniger W, et al. Tumor necrosis factor induces proliferation of neoplastic B cells from chronic lympho- cytic leukemia. Blood. 1989;73(5):1242- 1246.
18. Cordingley FT, Bianchi A, Hoffbrand AV, et al. Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet. 1988;1(8592):969- 971.
19. Woyach JA, Lin TS, Lucas MS, et al. A phase I/II study of rituximab and etaner- cept in patients with chronic lymphocytic leukemia and small lymphocytic lym- phoma. Leukemia. 2009;23(5):912-918.
20. Tartaglia LA, Goeddel DV. Two TNF recep- tors. Immunol Today. 1992;13(5):151-153.
21. Liu ZG, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector func- tions: JNK activation is not linked to apop- tosis while NF-kappaB activation prevents cell death. Cell. 1996;87(3):565-576.
22. Fas SC, Baumann S, Zhu JY, et al. Wogonin sensitizes resistant malignant cells to TNFalpha- and TRAIL-induced apoptosis. Blood. 2006;108(12):3700-3706.
23. Li-Weber M. Targeting apoptosis pathways in cancer by Chinese medicine. Cancer Lett. 2013;332(2):304-312.
24. Bichi R, Shinton SA, Martin ES, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA. 2002; 99(10):6955-6960.
25. McClanahan F, Riches JC, Miller S, et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Emicro-TCL1 CLL mouse model. Blood. 2015;126(2):212-221.
26. Hanna BS, McClanahan F, Yazdanparast H, et al. Depletion of CLL-associated
patrolling monocytes and macrophages controls disease development and repairs immune dysfunction in vivo. Leukemia. 2016;30(3):570-579.
27. Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lympho- cytic leukemia: fractions enriched in recent- ly born/divided and older/quiescent cells. Mol Med. 2011;17(11-12):1374-1382.
28. Hofbauer JP, Heyder C, Denk U, et al. Development of CLL in the TCL1 trans- genic mouse model is associated with severe skewing of the T-cell compartment homologous to human CLL. Leukemia. 2011;25(9):1452-1458.
29. Aderka D, Englemann H, Hornik V, et al. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991;51(20):5602-5607.
30. Waage A, Liabakk N, Lien E, Lamvik J, Espevik T. p55 and p75 tumor necrosis fac- tor receptors in patients with chronic lym- phocytic leukemia. Blood. 1992; 80(10):2577-2583.
31. Digel W, Schoniger W, Stefanic M, et al. Receptors for tumor necrosis factor on neo- plastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo. Blood. 1990;76(8):1607-1613.
32. Nakayama S, Yokote T, Tsuji M, et al. TNF- alpha receptor 1 expression predicts poor prognosis of diffuse large B-cell lymphoma, not otherwise specified. Am J Surg Pathol. 2014;38(8):1138-1146.
33. Hosono K, Yamada E, Endo H, et al. Increased tumor necrosis factor receptor 1 expression in human colorectal adenomas. World J Gastroenterol. 2012;18(38):5360- 5368.
34. de Miguel MP, Royuela M, Bethencourt FR, Santamaria L, Fraile B, Paniagua R. Immunoexpression of tumour necrosis fac- tor-alpha and its receptors 1 and 2 corre- lates with proliferation/apoptosis equilibri- um in normal, hyperplasic and carcinoma- tous human prostate. Cytokine. 2000; 12(5):535-538.
35. Mittal AK, Chaturvedi NK, Rai KJ, et al. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease. Mol Med. 2014; 20(1):290-301.
36. Muppidi JR, Tschopp J, Siegel RM. Life and death decisions: secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity. 2004;21(4):461- 465.
37. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF- kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol. 2000;164(4):2200-2206.
38. van Kooten C, Rensink I, Aarden L, van Oers R. Interleukin-4 inhibits both paracrine and autocrine tumor necrosis fac- tor-alpha-induced proliferation of B chronic
lymphocytic leukemia cells. Blood. 1992;80
(5):1299-1306.
39. Foa R, Massaia M, Cardona S, et al.
Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: a possible regulatory role of TNF in the progression of the disease. Blood. 1990;76(2):393-400.
40. Coscia M, Pantaleoni F, Riganti C, et al. IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and sub- ject to environmental prosurvival signals than mutated CLL B cells. Leukemia. 2011; 25(5):828-837.
41. Zettlitz KA, Lorenz V, Landauer K, et al. ATROSAB, a humanized antagonistic anti- tumor necrosis factor receptor one-specific antibody. MAbs. 2010;2(6):639-647.
42. Abe Y, Nomura T, Yoshioka Y, Kamada H, Tsunoda S, Tsutsumi Y. Anti-inflammatory effects of a novel TNFR1-selective antago- nistic TNF mutant on established murine collagen-induced arthritis. Adv Exp Med Biol. 2011;691:493-500.
43. Shibata H, Yoshioka Y, Ohkawa A, et al. The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models. Cytokine. 2008; 44(2):229-233.
44. Chung H, Jung Y-m, Shin D-H, et al. Anticancer effects of wogonin in both estrogen receptor-positive and -negative human breast cancer cell lines in vitro and in nude mice xenografts. Int J Cancer. 2008; 122(4):816-822.
45. Polier G, Ding J, Konkimalla BV, et al. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1. Cell Death Dis. 2011;2:e182.
46. Wang W, Guo Q-L, You Q-D, et al. The anticancer activities of wogonin in murine sarcoma S180 both in vitro and in vivo. Biol Pharm Bull. 2006;29(6):1132-1137.
47. Korn SH, Wouters EF, Vos N, Janssen- Heininger YM. Cytokine-induced activa- tion of nuclear factor-kappa B is inhibited by hydrogen peroxide through oxidative inactivation of IkappaB kinase. J Biol Chem. 2001;276(38):35693-35700.
48. Baumann S, Fas SC, Giaisi M, et al. Wogonin preferentially kills malignant lymphocytes and suppresses T-cell tumor growth by inducing PLCgamma1- and Ca2+-dependent apoptosis. Blood. 2008; 111(4):2354-2363.
49. Yang L, Zhang HW, Hu R, et al. Wogonin induces G1 phase arrest through inhibiting Cdk4 and cyclin D1 concomitant with an elevation in p21Cip1 in human cervical car- cinoma HeLa cells. Biochem Cell Biol. 2009;87(6):933-942.
50. Zhang HW, Yang Y, Zhang K, et al. Wogonin induced differentiation and G1 phase arrest of human U-937 leukemia cells via PKCdelta phosphorylation. Eur J Pharmacol. 2008;591(1-3):7-12.
haematologica | 2018; 103(4)
697